FIA
RNTX

FNY Investment Advisers’s Rein Therapeutics RNTX Stock Holding History

FNY Investment Advisers’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed – – 799
2022
Q3 		$0 Buy
+50
New +$211 ﹤0.01% 883
2020
Q3 		– Sell
-125
Closed -$2K – 632
2020
Q2 		$2K Buy
+125
New +$2.04K ﹤0.01% 370

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FNY Investment Advisers's RNTX Position: Q4 2022 in Review

FNY Investment Advisers sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 50 shares.

FNY Investment Advisers first reported a position in RNTX in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

  • FNY Investment Advisers reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 50 Rein Therapeutics shares in Q4 2022.
  • FNY Investment Advisers first reported a position in Rein Therapeutics in Q2 2020 and held it in 2 quarters.
  • FNY Investment Advisers's Rein Therapeutics position peaked at $2K in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on FNY Investment Advisers's 13F filing for Q4 2022, filed 10 Jan 2023.